Literature DB >> 12610356

Rapid immunohistochemistry for cytokeratin in the intraoperative evaluation of sentinel lymph nodes for metastatic breast carcinoma.

Robyn A Beach1, Diane Lawson, Sandra M Waldrop, Cynthia Cohen.   

Abstract

The sensitivity and specificity of detecting metastatic breast carcinoma in sentinel lymph nodes using a rapid immunohistochemistry technique was determined and compared with methods currently used at the authors' institution. At the time of intraoperative consultation, after routine diagnostic touch preparations and frozen sections were prepared, 6-microm frozen sections of 72 sentinel lymph nodes from 32 patients with breast carcinoma were placed on plus slides, fixed in cold acetone for 2 or 3 minutes, and stored at -70 degrees C. These sections were immunostained with a prediluted broad-spectrum anticytokeratin monoclonal antibody coupled to an inert polymer with horseradish peroxidase (DAKO EPOS). Slides were ready for interpretation within 16 minutes and were scored as positive, negative, or equivocal for metastatic carcinoma. Results were compared with those of the intraoperative touch preparations and frozen sections and with paraffin-embedded, hematoxylin and eosin-stained, and AE1/AE3 immunostained permanent sections. Fourteen (19%) sentinel lymph nodes were positive for metastatic carcinoma in 13 patients. All methods tested were 100% specific. The rapid immunohistochemistry method was the least sensitive (57% sensitivity) of all methods used to detect metastasis. Routine diagnostic touch preparations, frozen sections, and permanent sections had sensitivities of 69%, 86%, and 100% respectively. In conclusion, this rapid immunohistochemistry method would not be helpful in intraoperative assessment of sentinel lymph nodes in breast cancer patients due to its low sensitivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610356     DOI: 10.1097/00129039-200303000-00008

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  5 in total

1.  Frozen section is superior to imprint cytology for the intra-operative assessment of sentinel lymph node metastasis in stage I breast cancer patients.

Authors:  Miki Mori; Keiichiro Tada; Motoko Ikenaga; Yumi Miyagi; Seiichiro Nishimura; Kaoru Takahashi; Masujiro Makita; Takuji Iwase; Fujio Kasumi; Mituru Koizumi
Journal:  World J Surg Oncol       Date:  2006-05-17       Impact factor: 2.754

2.  Accuracy of Intraoperative Frozen Section of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Carcinoma.

Authors:  Anne Grabenstetter; Tracy-Ann Moo; Sabina Hajiyeva; Peter J Schüffler; Pallavi Khattar; Maria A Friedlander; Maura A McCormack; Monica Raiss; Emily C Zabor; Andrea Barrio; Monica Morrow; Marcia Edelweiss
Journal:  Am J Surg Pathol       Date:  2019-10       Impact factor: 6.394

3.  Clinicopathologic findings in failed descemet stripping automated endothelial keratoplasty.

Authors:  Qing Zhang; J Bradley Randleman; R Doyle Stulting; W Barry Lee; Donald U Stone; Alan M Kozarsky; Hans E Grossniklaus
Journal:  Arch Ophthalmol       Date:  2010-08

4.  A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer.

Authors:  Savitri Krishnamurthy; Funda Meric-Bernstam; Anthony Lucci; Rosa F Hwang; Henry M Kuerer; Gildy Babiera; Fredrick C Ames; Barry W Feig; Merrick I Ross; Eva Singletary; Kelly K Hunt; Isabelle Bedrosian
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

5.  Quantitative molecular analysis of sentinel lymph node may be predictive of axillary node status in breast cancer classified by molecular subtypes.

Authors:  Simonetta Buglioni; Franco Di Filippo; Irene Terrenato; Beatrice Casini; Enzo Gallo; Ferdinando Marandino; Carlo L Maini; Rossella Pasqualoni; Claudio Botti; Simona Di Filippo; Edoardo Pescarmona; Marcella Mottolese
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.